卡格列净与血管紧张素转换酶抑制剂联合治疗早期糖尿病肾病的疗效

Efficacy and Safety of Canagliflozin combined with ACEI in the Treatment of Early Diabetic Nepbropathy

目的探讨卡格列净联合血管紧张素转换酶抑制剂(ACEI)治疗早期糖尿病肾病的临床疗效和安全性。方法选取2018年8月至2019年12月期间80例确诊为早期糖尿病肾病患者,收集临床资料进行回顾性分析。按照每组40例随机分为两组。对照组应用ACEI贝那普利治疗,研究组在对照组的基础上加用了卡格列净,两组患者均治疗12周,比较两组的治疗效果,并观察卡格列净临床治疗的安全性。结果与治疗前相比,两组患者治疗后的各项指标均有好转,差异有显著性(P <0.05),研究组患者的尿微量蛋白及尿蛋白水平、尿素氮、肌酐、糖化血红蛋白均低于对照组,差异有显著性(P <0.05),两组患者均无严重不良反应。结论卡格列净联合ACEI治疗早期糖尿病肾病的疗效优于单用ACEI,具有良好的应用前景。

Objective To investigate the clinical efficacy and safety of canagliflozin combined with angiotensin converting enzyme inhibitor(ACEI)in the treatment of early diabetic nephropathy.Methods Eighty patients diagnosed with early nephropathy in the hospital from August 2018 to December 2019 were enrolled in the study.The patients were randomly divided into two groups according to the digital table method,with 40 cases in each group.The control group was treated with ACEI benazepril.The research group was added canaglifl ozin on the basis of treatment in control group.Both groups were treated for 12 weeks.The therapeutic eff ects of the two groups were compared and canagliflozin safety of clinical treatment.Results Compared with before treatment,the indexes of the two groups were signifi cantly improved after treatment,the diff erence was statistically signifi cant(P<0.05).The levels of HbA1c,urea nitrogen,creatnine,uricacid,urinary albumin and urine protein in research group were all lower than those in control group,and the diff erence was statistically signifi cant(P<0.05).No serious adverse reactions occurred in either group.Conclusion The eff ect of canaglifl ozin combined with ACEI in the treatment of early diabetics nephropathy is better than that of ACEI alone,and it has a good application prospect.